Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Appointments reinforce technical operations and investor engagement as the company advances its clinical programs
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones.
Tiwari will lead Faeth’s technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company’s PIKTOR clinical development program and potential future commercialization. Biegler will lead the company’s investor relations function and engagement with current and prospective investors.
“Expanding our leadership team is an important part of preparing Faeth for its next stage of development,” said Anand Parikh, Chairman, President and Chief Executive Officer of Faeth Therapeutics. “Deepak brings extensive experience in CMC, manufacturing and supply chain across the biopharmaceutical industry, while Matt brings experience spanning biotechnology equity research, clinical development strategy and the capital markets. Their appointments add capabilities directly relevant to the continued development of PIKTOR and our engagement with the investment community.”
